A	O
germline	B-DNA
TaqI	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
in	O
the	O
progesterone	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
ovarian	O
carcinoma	O
[	O
see	O
comments	O
]	O

Clinical	O
outcome	O
in	O
ovarian	O
carcinoma	O
is	O
predicted	O
by	O
progesterone	B-protein
receptor	I-protein
status	O
,	O
indicating	O
an	O
endocrine	O
aspect	O
to	O
this	O
disease	O
.	O

Peripheral	B-DNA
leucocyte	I-DNA
genomic	I-DNA
DNAs	I-DNA
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O

Southern	O
analysis	O
using	O
a	O
human	B-DNA
progesterone	I-DNA
receptor	I-DNA
(	I-DNA
hPR	I-DNA
)	I-DNA
cDNA	I-DNA
probe	I-DNA
identified	O
a	O
germline	B-DNA
TaqI	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
(	O
RFLP	B-DNA
)	O
defined	O
by	O
two	O
alleles	O
:	O
T1	B-DNA
,	O
represented	O
by	O
a	O
2.7	B-DNA
kb	I-DNA
fragment	I-DNA
;	O
and	O
T2	B-DNA
,	O
represented	O
by	O
a	O
1.9	B-DNA
kb	I-DNA
fragment	I-DNA
and	O
characterised	O
by	O
an	O
additional	O
TaqI	B-DNA
restriction	I-DNA
site	I-DNA
with	O
respect	O
to	O
T1	B-DNA
.	O

An	O
over-representation	O
of	O
T2	B-DNA
in	O
ovarian	O
cancer	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
pooled	O
Irish/German	O
population	O
(	O
P	O
<	O
0.025	O
)	O
was	O
observed	O
.	O

A	O
difference	O
(	O
P	O
<	O
0.02	O
)	O
in	O
the	O
distribution	O
of	O
the	O
RFLP	B-DNA
genotypes	O
between	O
Irish	O
and	O
German	O
control	O
populations	O
was	O
also	O
observed	O
.	O

The	O
allele	O
distributions	O
could	O
not	O
be	O
shown	O
to	O
differ	O
significantly	O
from	O
Hardy-Weinberg	O
distribution	O
in	O
any	O
subgroup	O
.	O

Using	O
hPR	B-DNA
cDNA	I-DNA
region-specific	I-DNA
probes	I-DNA
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	B-DNA
G	I-DNA
of	O
the	O
hPR	B-DNA
gene	I-DNA
.	O

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1995	NULL
)	NULL
71	NULL
,	NULL
451-455	NULL
©	NULL
1995	NULL
Stockton	NULL
Press	NULL
-	NULL
All	NULL
rights	NULL
reserved	NULL
0007-0920/95	NULL
$	NULL
9.00	NULL
A	NULL
germline	NULL
7agl	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
in	NULL
the	NULL
progesterone	NULL
receptor	NULL
gene	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
NJ	NULL
McKenna	NULL
'	NULL
,	NULL
DG	NULL
Kieback®*	NULL
,	NULL
DN	NULL
Carney	NULL
}	NULL
,	NULL
M	NULL
Fanning	NULL
'	NULL
,	NULL
J	NULL
McLinden®	NULL
and	NULL
DR	NULL
Headon	NULL
'	NULL
'Cell	NULL
and	NULL
Molecular	NULL
Biology	NULL
Group	NULL
,	NULL
Department	NULL
of	NULL
Biochemistry	NULL
,	NULL
University	NULL
College	NULL
Galway	NULL
,	NULL
Galway	NULL
,	NULL
Ireland	NULL
;	NULL
*Department	NULL
of	NULL
Obstetrics	NULL
and	NULL
Gynaecology	NULL
,	NULL
University	NULL
of	NULL
Ulm	NULL
,	NULL
Prittwitzstrafe	NULL
43	NULL
,	NULL
D-89075	NULL
Ulm	NULL
,	NULL
Germany	NULL
;	NULL
'Department	NULL
of	NULL
Oncology	NULL
,	NULL
Mater	NULL
Misericordiae	NULL
Hospital	NULL
,	NULL
Eccles	NULL
St.	NULL
,	NULL
Dublin	NULL
7	NULL
,	NULL
Ireland	NULL
;	NULL
*American	NULL
Biogenetic	NULL
Sciences	NULL
,	NULL
South	NULL
Bend	NULL
,	NULL
Notre	NULL
Dame	NULL
,	NULL
Indiana	NULL
46556	NULL
,	NULL
USA	NULL
.	NULL

Samamary	NULL
-	NULL
Clinical	NULL
outcome	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
is	NULL
predicted	NULL
by	NULL
progesterone	NULL
receptor	NULL
status	NULL
.	NULL

indicating	NULL
an	NULL
endocrine	NULL
aspect	NULL
to	NULL
this	NULL
disease	NULL
.	NULL

Peripheral	NULL
leucocyte	NULL
genomic	NULL
DNAs	NULL
were	NULL
obtained	NULL
from	NULL
41	NULL
patients	NULL
with	NULL
primary	NULL
ovarian	NULL
carcinoma	NULL
and	NULL
83	NULL
controls	NULL
from	NULL
Ireland	NULL
,	NULL
as	NULL
well	NULL
as	NULL
from	NULL
26	NULL
primary	NULL
ovarian	NULL
carcinoma	NULL
patients	NULL
and	NULL
101	NULL
controls	NULL
in	NULL
Germany	NULL
.	NULL

Southern	NULL
analysis	NULL
using	NULL
a	NULL
human	NULL
progesterone	NULL
receptor	NULL
(	NULL
hPR	NULL
)	NULL
cDNA	NULL
probe	NULL
identified	NULL
a	NULL
germline	NULL
Tagl	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
(	NULL
RFLP	NULL
)	NULL
defined	NULL
by	NULL
two	NULL
alleles	NULL
:	NULL
Tl	NULL
.	NULL

represented	NULL
by	NULL
a	NULL
2.7	NULL
kb	NULL
fragment	NULL
;	NULL
and	NULL
T2	NULL
,	NULL
represented	NULL
by	NULL
a	NULL
1.9	NULL
kb	NULL
fragment	NULL
and	NULL
characterised	NULL
by	NULL
an	NULL
additional	NULL
Taq	NULL
]	NULL
restriction	NULL
site	NULL
with	NULL
respect	NULL
to	NULL
Tl	NULL
.	NULL

An	NULL
over-representation	NULL
of	NULL
T2	NULL
in	NULL
ovarian	NULL
cancer	NULL
patients	NULL
compared	NULL
with	NULL
controls	NULL
in	NULL
the	NULL
pooled	NULL
Irish/German	NULL
population	NULL
(	NULL
P	NULL
<	NULL
0.025	NULL
)	NULL
was	NULL
observed	NULL
.	NULL

A	NULL
difference	NULL
(	NULL
P	NULL
<	NULL
0.02	NULL
)	NULL
in	NULL
the	NULL
distribution	NULL
of	NULL
the	NULL
RFLP	NULL
genotypes	NULL
between	NULL
Irish	NULL
and	NULL
German	NULL
control	NULL
populations	NULL
was	NULL
also	NULL
observed	NULL
.	NULL

The	NULL
allele	NULL
distributions	NULL
could	NULL
not	NULL
be	NULL
shown	NULL
to	NULL
differ	NULL
significantly	NULL
from	NULL
Hardy-Weinberg	NULL
distribution	NULL
in	NULL
any	NULL
subgroup	NULL
.	NULL

Using	NULL
hPR	NULL
cDNA	NULL
region-specific	NULL
probes	NULL
,	NULL
the	NULL
extra	NULL
Tag	NULL
!	NULL

restriction	NULL
site	NULL
was	NULL
mapped	NULL
to	NULL
intron	NULL
G	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
.	NULL

Keywords	NULL
:	NULL
progesterone	NULL
receptor	NULL
gene	NULL
;	NULL
RFLP	NULL
;	NULL
ovarian	NULL
carcinoma	NULL
Ovarian	NULL
cancer	NULL
is	NULL
the	NULL
leading	NULL
cause	NULL
of	NULL
death	NULL
among	NULL
patients	NULL
with	NULL
gynaecological	NULL
cancers	NULL
with	NULL
a	NULL
5	NULL
year	NULL
survival	NULL
rate	NULL
,	NULL
averaged	NULL
over	NULL
all	NULL
stages	NULL
,	NULL
of	NULL
29-32	NULL
%	NULL
(	NULL
Scully	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

Such	NULL
high	NULL
mortality	NULL
is	NULL
due	NULL
largely	NULL
to	NULL
the	NULL
insidious	NULL
early	NULL
progression	NULL
of	NULL
the	NULL
disease	NULL
and	NULL
consequent	NULL
detection	NULL
at	NULL
an	NULL
advanced	NULL
tumour	NULL
stage	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
a	NULL
sufficiently	NULL
specific	NULL
and	NULL
sensitive	NULL
screening	NULL
test	NULL
for	NULL
diagnosis	NULL
or	NULL
prognosis	NULL
of	NULL
the	NULL
disease	NULL
compounds	NULL
the	NULL
problem	NULL
of	NULL
its	NULL
treatment	NULL
.	NULL

Progesterone	NULL
receptor	NULL
estimation	NULL
yields	NULL
prognostic	NULL
information	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
(	NULL
Slotman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Chadha	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Noguchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
indicating	NULL
a	NULL
positive	NULL
relationship	NULL
between	NULL
progesterone	NULL
receptor	NULL
expression	NULL
and	NULL
prognosis	NULL
.	NULL

The	NULL
cDNA	NULL
for	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
(	NULL
hPR	NULL
)	NULL
was	NULL
first	NULL
cloned	NULL
and	NULL
sequenced	NULL
by	NULL
Misrahi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
and	NULL
later	NULL
by	NULL
Kastner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
has	NULL
recently	NULL
been	NULL
described	NULL
(	NULL
Figure	NULL
1a	NULL
)	NULL
(	NULL
Misrahi	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
multiple	NULL
forms	NULL
of	NULL
the	NULL
hPR	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
Scharl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Loss	NULL
of	NULL
heterozygosity	NULL
at	NULL
the	NULL
11g23	NULL
locus	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
Foulkes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
in	NULL
this	NULL
region	NULL
of	NULL
a	NULL
tumour-suppressor	NULL
gene	NULL
relevant	NULL
to	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

The	NULL
hPR	NULL
gene	NULL
has	NULL
been	NULL
mapped	NULL
by	NULL
separate	NULL
groups	NULL
to	NULL
the	NULL
11q22-q23	NULL
locus	NULL
(	NULL
Rousseau-Merck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Mattei	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
an	NULL
ovarian	NULL
carcinoma	NULL
cell	NULL
line	NULL
with	NULL
chromosome	NULL
11	NULL
has	NULL
resulted	NULL
in	NULL
suppression	NULL
of	NULL
growth	NULL
(	NULL
Cao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
further	NULL
suggestive	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
tumour-suppressive	NULL
regions	NULL
on	NULL
this	NULL
chromosome	NULL
.	NULL

Restriction	NULL
fragment	NULL
length	NULL
polymorphisms	NULL
(	NULL
RFLPs	NULL
)	NULL
are	NULL
somatic	NULL
or	NULL
hereditary	NULL
variations	NULL
in	NULL
the	NULL
length	NULL
of	NULL
a	NULL
DNA	NULL
fragment	NULL
yielded	NULL
by	NULL
specific	NULL
restriction	NULL
endonuclease	NULL
diges-tion	NULL
.	NULL

Steroid	NULL
hormone	NULL
receptor	NULL
gene	NULL
RFLPs	NULL
have	NULL
been	NULL
previously	NULL
studied	NULL
in	NULL
human	NULL
female	NULL
malignancies	NULL
.	NULL

A	NULL
HindIII	NULL
polymorphism	NULL
in	NULL
the	NULL
progesterone	NULL
receptor	NULL
gene	NULL
exhibited	NULL
non-Mendelian	NULL
distribution	NULL
in	NULL
primary	NULL
breast	NULL
tumours	NULL
(	NULL
Fuqua	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
HindIII	NULL
polymorphism	NULL
of	NULL
the	NULL
oestrogen	NULL
receptor	NULL
gene	NULL
was	NULL
found	NULL
to	NULL
correlate	NULL
with	NULL
progesterone	NULL
receptor	NULL
expression	NULL
in	NULL
primary	NULL
breast	NULL
tumours	NULL
(	NULL
Wanless	NULL
et	NULL
Correspondence	NULL
:	NULL
DR	NULL
Headon	NULL
*Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Obstetrics	NULL
and	NULL
Gynaecology	NULL
,	NULL
Baylor	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Houston	NULL
,	NULL
Texas	NULL
77030	NULL
,	NULL
USA	NULL
.	NULL

Received	NULL
22	NULL
September	NULL
1994	NULL
;	NULL
revised	NULL
31	NULL
October	NULL
1994	NULL
;	NULL
accepted	NULL
1	NULL
November	NULL
1994	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
specific	NULL
pattern	NULL
of	NULL
differential	NULL
expression	NULL
of	NULL
the	NULL
chicken	NULL
ovalbumin	NULL
upstream	NULL
promoter	NULL
transcription	NULL
factor	NULL
(	NULL
COUP-TF	NULL
)	NULL
,	NULL
an	NULL
orphan	NULL
of	NULL
the	NULL
steroid	NULL
hormone	NULL
receptor	NULL
superfamily	NULL
,	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
human	NULL
ovarian	NULL
cancer	NULL
cell	NULL
lines	NULL
(	NULL
Kieback	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
this	NULL
novel	NULL
steroid	NULL
receptor	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

The	NULL
Tag	NULL
!	NULL

restriction	NULL
endonuclease	NULL
recognition	NULL
site	NULL
TCGA	NULL
,	NULL
containing	NULL
all	NULL
four	NULL
base	NULL
pairs	NULL
found	NULL
in	NULL
DNA	NULL
,	NULL
allows	NULL
analysis	NULL
of	NULL
all	NULL
12	NULL
potential	NULL
single	NULL
base	NULL
pair	NULL
mutations	NULL
(	NULL
Sandy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
in	NULL
this	NULL
recognition	NULL
site	NULL
of	NULL
the	NULL
di-nucleotide	NULL
sequence	NULL
CpG	NULL
is	NULL
of	NULL
particular	NULL
importance	NULL
given	NULL
that	NULL
deamination	NULL
of	NULL
cytosine	NULL
or	NULL
S-methylcytosine	NULL
in	NULL
CpG	NULL
dinucleotides	NULL
is	NULL
a	NULL
common	NULL
mechanism	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
C	NULL
to	NULL
T	NULL
transitions	NULL
in	NULL
cancer-related	NULL
genes	NULL
(	NULL
Hollstein	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

For	NULL
these	NULL
reasons	NULL
,	NULL
Tagl	NULL
is	NULL
especially	NULL
useful	NULL
in	NULL
discerning	NULL
polymorphic	NULL
alleles	NULL
by	NULL
RFLP	NULL
analysis	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
the	NULL
status	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
in	NULL
primary	NULL
ovarian	NULL
carcinoma	NULL
,	NULL
we	NULL
analysed	NULL
peripheral	NULL
leucocyte	NULL
genomic	NULL
DNA	NULL
from	NULL
ovarian	NULL
carcinoma	NULL
patients	NULL
and	NULL
controls	NULL
for	NULL
appearance	NULL
of	NULL
a	NULL
germline	NULL
Tagl	NULL
RFLP	NULL
in	NULL
the	NULL
hPR	NULL
gene	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
and	NULL
hPR	NULL
cDNA	NULL
region-specific	NULL
probes	NULL
Refer	NULL
to	NULL
Figure	NULL
1	NULL
.	NULL

Screening	NULL
of	NULL
a	NULL
Agtll	NULL
random-primed	NULL
T47D	NULL
human	NULL
breast	NULL
cancer	NULL
cell	NULL
line	NULL
cDNA	NULL
library	NULL
with	NULL
a	NULL
2	NULL
kb	NULL
chick	NULL
oviduct	NULL
progesterone	NULL
receptor	NULL
cDNA	NULL
(	NULL
both	NULL
gifts	NULL
from	NULL
Dr	NULL
BW	NULL
O'Malley	NULL
,	NULL
Baylor	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
,	NULL
USA	NULL
)	NULL
yielded	NULL
a	NULL
1.85	NULL
kb	NULL
cDNA	NULL
,	NULL
hPR-1	NULL
,	NULL
which	NULL
was	NULL
subsequently	NULL
cloned	NULL
in	NULL
pGEM-4	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
USA	NULL
)	NULL
using	NULL
EcoRI	NULL
to	NULL
yield	NULL
pGEM-4-hPR-1	NULL
(	NULL
Clifford-Brougham	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
hPR-1	NULL
cDNA	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
consists	NULL
of	NULL
1846	NULL
base	NULL
pairs	NULL
(	NULL
bp	NULL
)	NULL
,	NULL
of	NULL
which	NULL
1084	NULL
bp	NULL
represent	NULL
3	NULL
'	NULL
coding	NULL
sequence	NULL
and	NULL
the	NULL
remaining	NULL
762	NULL
bp	NULL
is	NULL
3'-untranslated	NULL
sequence	NULL
.	NULL

hPR-1	NULL
probe	NULL
was	NULL
prepared	NULL
for	NULL
Southern	NULL
analysis	NULL
by	NULL
digestion	NULL
of	NULL
pGEM-4-hPR-1	NULL
with	NULL
EcoRI	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
,	NULL
under	NULL
conditions	NULL
specified	NULL
by	NULL
the	NULL
manufacturer	NULL
,	NULL
and	NULL
purified	NULL
twice	NULL
by	NULL
electroelution	NULL
after	NULL
separation	NULL
on	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
electro-phoresis	NULL
gel	NULL
.	NULL

The	NULL
hPR-2	NULL
cDNA	NULL
probe	NULL
(	NULL
Figure	NULL
lc	NULL
)	NULL
was	NULL
generated	NULL
by	NULL
PCR	NULL
using	NULL
sense	NULL
primer	NULL
no	NULL
.	NULL

1	NULL
(	NULL
5-TCGAGCTC-	NULL
Progesterone	NULL
receptor	NULL
gene	NULL
RFLP	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
NJ	NULL
McKenna	NULL
et	NULL
al	NULL
452	NULL
ATG	NULL
1	NULL
1637	NULL
1789	NULL
1906	NULL
(	NULL
ml	NULL
E1	NULL
(	NULL
b	NULL
)	NULL
TGA	NULL
2212	NULL
2357	NULL
2489	NULL
2646	NULL
2799	NULL
3561	NULL
A	NULL
3-H	NULL
}	NULL
;	NULL
D	NULL
‘	NULL
Eﬂj	NULL
G	NULL
———L_H_	NULL
HH	NULL
E2	NULL
Es	NULL
-	NULL
p	NULL
Es	NULL
{	NULL
u	NULL
E6	NULL
E8	NULL
<	NULL
fire	NULL
fielfe	NULL
fi	NULL
(	NULL
-a	NULL
--	NULL
-	NULL
``	NULL
T	NULL
T	NULL
T	NULL
T	NULL
1	NULL
(	NULL
@	NULL
)	NULL
i	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
(	NULL
d	NULL
)	NULL
--	NULL
--	NULL
-	NULL
Figure	NULL
1	NULL
(	NULL
a	NULL
)	NULL
Structure	NULL
of	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
(	NULL
hPR	NULL
)	NULL
gene	NULL
(	NULL
Misrahi	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Numbers	NULL
above	NULL
the	NULL
exons	NULL
(	NULL
E1-E8	NULL
)	NULL
refer	NULL
to	NULL
cDNA	NULL
base	NULL
pair	NULL
number	NULL
(	NULL
numbered	NULL
from	NULL
ATG1	NULL
)	NULL
.	NULL

T	NULL
,	NULL
location	NULL
of	NULL
Tagl	NULL
cDNA	NULL
restriction	NULL
sites	NULL
according	NULL
to	NULL
Kastner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Introns	NULL
(	NULL
A-G	NULL
)	NULL
are	NULL
represented	NULL
by	NULL
broken	NULL
thin	NULL
lines	NULL
.	NULL

The	NULL
locations	NULL
of	NULL
the	NULL
translation	NULL
initiation	NULL
(	NULL
ATG	NULL
)	NULL
and	NULL
translation	NULL
termination	NULL
(	NULL
TGA	NULL
)	NULL
codons	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
hPR	NULL
DNA-binding	NULL
domain	NULL
is	NULL
encoded	NULL
by	NULL
exons	NULL
2	NULL
and	NULL
3	NULL
.	NULL

Exon	NULL
4	NULL
encodes	NULL
the	NULL
hinge	NULL
domain	NULL
and	NULL
part	NULL
of	NULL
the	NULL
hormone-binding	NULL
domain	NULL
.	NULL

Exons	NULL
5-8	NULL
encode	NULL
the	NULL
remainder	NULL
of	NULL
the	NULL
hPR	NULL
hormone-binding	NULL
domain	NULL
(	NULL
Misrahi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
probes	NULL
used	NULL
in	NULL
Southern	NULL
analysis	NULL
(	NULL
b	NULL
)	NULL
hPR-1	NULL
,	NULL
(	NULL
c	NULL
)	NULL
hPR-2	NULL
and	NULL
(	NULL
d	NULL
)	NULL
hPR-3	NULL
,	NULL
are	NULL
shown	NULL
.	NULL

ACAGCGTTTCTATCAA-3	NULL
``	NULL
)	NULL
corresponding	NULL
to	NULL
hPR	NULL
cDNA	NULL
sequence	NULL
2593-2616	NULL
bp	NULL
(	NULL
numbered	NULL
from	NULL
ATG1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
antisense	NULL
primer	NULL
no	NULL
.	NULL

2	NULL
(	NULL
5-AAAACCTACAAAACCCACAA-TACT-3	NULL
'	NULL
)	NULL
(	NULL
hPR	NULL
cDNA	NULL
sequence	NULL
3471-3494	NULL
bp	NULL
,	NULL
numbered	NULL
from	NULL
ATG1	NULL
)	NULL
(	NULL
Kastner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

hPR-3	NULL
probe	NULL
(	NULL
Figure	NULL
1d	NULL
)	NULL
was	NULL
generated	NULL
by	NULL
PCR	NULL
amplification	NULL
using	NULL
the	NULL
sense	NULL
primer	NULL
no	NULL
.	NULL

3	NULL
(	NULL
5-TCGACTTAAGAGAAAAAATCTTAC-3	NULL
``	NULL
)	NULL
(	NULL
hPR	NULL
cDNA	NULL
sequence	NULL
3133-3156	NULL
bp	NULL
,	NULL
numbered	NULL
from	NULL
ATG1	NULL
)	NULL
(	NULL
Kastner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
and	NULL
primer	NULL
no	NULL
.	NULL

2	NULL
.	NULL

Polymerase	NULL
chain	NULL
reactions	NULL
(	NULL
PCRs	NULL
)	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
a	NULL
100	NULL
pul	NULL
final	NULL
volume	NULL
of	NULL
10	NULL
mM	NULL
Tns-HCl	NULL
,	NULL
1.5	NULL
mM	NULL
magnesium	NULL
chloride	NULL
and	NULL
50	NULL
mM	NULL
potassium	NULL
chloride	NULL
using	NULL
50	NULL
ng	NULL
each	NULL
of	NULL
the	NULL
oligonucleotide	NULL
primer	NULL
pair	NULL
,	NULL
100	NULL
ng	NULL
of	NULL
template	NULL
pGem-4-hPR-1	NULL
,	NULL
1.5	NULL
mm	NULL
of	NULL
each	NULL
dNTP	NULL
and	NULL
2.5	NULL
units	NULL
of	NULL
Tag	NULL
DNA	NULL
polymerase	NULL
(	NULL
all	NULL
PCR	NULL
reagents	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Each	NULL
amplification	NULL
cycle	NULL
(	NULL
30	NULL
in	NULL
total	NULL
)	NULL
consisted	NULL
of	NULL
a	NULL
90s	NULL
denaturation	NULL
step	NULL
at	NULL
94°C	NULL
,	NULL
a	NULL
90	NULL
s	NULL
annealing	NULL
step	NULL
at	NULL
55°C	NULL
and	NULL
a	NULL
90	NULL
s	NULL
extension	NULL
step	NULL
at	NULL
72°C	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
purified	NULL
on	NULL
a	NULL
1	NULL
%	NULL
low-melt	NULL
agarose	NULL
gel	NULL
(	NULL
NuSieve	NULL
GTG	NULL
;	NULL
FMC	NULL
Bioproducts	NULL
,	NULL
Rockland	NULL
,	NULL
ME	NULL
,	NULL
USA	NULL
)	NULL
before	NULL
nick	NULL
translation	NULL
*P-labelling	NULL
.	NULL

DNA	NULL
extraction	NULL
,	NULL
restriction	NULL
enzyme	NULL
digestion	NULL
and	NULL
Southern	NULL
blot	NULL
analysis	NULL
Genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
from	NULL
whole	NULL
human	NULL
blood	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
of	NULL
Miller	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Thawed	NULL
whole	NULL
blood	NULL
was	NULL
incubated	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
10	NULL
mM	NULL
Tris-HCl-10	NULL
mM	NULL
EDTA	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
5000	NULL
r.p.m	NULL
.	NULL

for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
the	NULL
pellet	NULL
resuspended	NULL
in	NULL
10	NULL
mM	NULL
Tris-HCl-10	NULL
mM	NULL
EDTA	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
5000	NULL
r.p.m	NULL
.	NULL

for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
the	NULL
pellet	NULL
washed	NULL
in	NULL
10	NULL
mM	NULL
Tris-HCl-	NULL
10	NULL
mM	NULL
EDTA	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
.	NULL

After	NULL
centrifugation	NULL
at	NULL
5000	NULL
r.p.m	NULL
.	NULL

for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
10	NULL
mm	NULL
Tris-HCl	NULL
pH	NULL
8.0-5	NULL
mM	NULL
EDTA-1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulphate	NULL
(	NULL
SDS	NULL
)	NULL
-0.4	NULL
%	NULL
Proteinase	NULL
K	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
incubated	NULL
at	NULL
37°C	NULL
overnight	NULL
,	NULL
and	NULL
treated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Miller	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

After	NULL
spectrophotometric	NULL
determination	NULL
of	NULL
DNA	NULL
concentration	NULL
and	NULL
purity	NULL
,	NULL
20	NULL
ug	NULL
of	NULL
each	NULL
DNA	NULL
was	NULL
digested	NULL
to	NULL
completion	NULL
with	NULL
40	NULL
units	NULL
of	NULL
Tagl	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
300	NULL
pul	NULL
at	NULL
65°C	NULL
overnight	NULL
under	NULL
conditions	NULL
specified	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

The	NULL
digested	NULL
DNA	NULL
samples	NULL
were	NULL
fractionated	NULL
on	NULL
a	NULL
0.8	NULL
%	NULL
agarose	NULL
gel	NULL
and	NULL
following	NULL
denaturation	NULL
(	NULL
1.5	NULL
M	NULL
sodium	NULL
chloride	NULL
,	NULL
0.5	NULL
M	NULL
sodium	NULL
hydroxide	NULL
)	NULL
and	NULL
neutralisation	NULL
(	NULL
1.5	NULL
M	NULL
sodium	NULL
chloride	NULL
,	NULL
0.5	NULL
m	NULL
Tris	NULL
pH	NULL
7.2	NULL
,	NULL
0.001	NULL
M	NULL
EDTA	NULL
)	NULL
DNA	NULL
was	NULL
transferred	NULL
from	NULL
the	NULL
gel	NULL
in	NULL
20	NULL
x	NULL
SSC	NULL
(	NULL
3	NULL
M	NULL
sodium	NULL
chloride	NULL
,	NULL
0.3	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
by	NULL
capillary	NULL
action	NULL
to	NULL
a	NULL
6	NULL
x	NULL
SSC-soaked	NULL
nylon	NULL
membrane	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

After	NULL
overnight	NULL
transfer	NULL
of	NULL
DNA	NULL
,	NULL
the	NULL
membranes	NULL
were	NULL
washed	NULL
in	NULL
2	NULL
x	NULL
SSC	NULL
and	NULL
baked	NULL
for	NULL
2h	NULL
at	NULL
80°C	NULL
.	NULL

Low-melt	NULL
agarose	NULL
gel-purified	NULL
probe	NULL
was	NULL
``	NULL
P-labelled	NULL
uing	NULL
Prime-A-Gene	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
USA	NULL
)	NULL
to	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
2	NULL
x	NULL
10®	NULL
c.p.m	NULL
.	NULL

ug~	NULL
'	NULL
.	NULL

Prehybri-	NULL
disation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
6	NULL
x	NULL
SSC	NULL
,	NULL
5	NULL
x	NULL
Denhardt	NULL
's	NULL
solution	NULL
[	NULL
0.02	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
0.02	NULL
%	NULL
polyvinylpyrollidone	NULL
,	NULL
0.02	NULL
%	NULL
Ficoll	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
]	NULL
,	NULL
0.5	NULL
%	NULL
SDS	NULL
and	NULL
100	NULL
ug	NULL
ml~	NULL
'	NULL
denatured	NULL
salmon	NULL
sperm	NULL
DNA	NULL
at	NULL
65°C	NULL
for	NULL
3	NULL
h.	NULL
The	NULL
membranes	NULL
were	NULL
incubated	NULL
in	NULL
hybridisation	NULL
fluid	NULL
(	NULL
as	NULL
prehybridisation	NULL
fluid	NULL
,	NULL
containing	NULL
5	NULL
x	NULL
106	NULL
%	NULL
c.p.m	NULL
.	NULL

``	NULL
P	NULL
labelled	NULL
probe	NULL
)	NULL
at	NULL
65°C	NULL
for	NULL
18-24	NULL
h.	NULL
Membranes	NULL
were	NULL
washed	NULL
to	NULL
a	NULL
final	NULL
stringency	NULL
of	NULL
0.5	NULL
x	NULL
SSC-0.5	NULL
%	NULL
SDS	NULL
at	NULL
65°C	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
exposed	NULL
to	NULL
Kodak	NULL
X-OMAT	NULL
XAR-5	NULL
autoradiographic	NULL
film	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
USA	NULL
)	NULL
at	NULL
-70°C	NULL
with	NULL
intensifying	NULL
screens	NULL
for	NULL
48-72	NULL
h.	NULL
Statistical	NULL
analysis	NULL
Comparison	NULL
of	NULL
the	NULL
observed	NULL
genotypic	NULL
distribution	NULL
of	NULL
the	NULL
Taql	NULL
hPR	NULL
alleles	NULL
between	NULL
subgroups	NULL
was	NULL
carried	NULL
out	NULL
,	NULL
where	NULL
appropriate	NULL
,	NULL
using	NULL
y	NULL
'	NULL
analysis	NULL
Calculation	NULL
of	NULL
expected	NULL
genotypic	NULL
frequencies	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
Hardy-Weinberg	NULL
equation	NULL
and	NULL
these	NULL
expected	NULL
frequencies	NULL
were	NULL
compared	NULL
by	NULL
1	NULL
``	NULL
analysis	NULL
,	NULL
using	NULL
Yates	NULL
'	NULL
correction	NULL
for	NULL
expected	NULL
classes	NULL
less	NULL
than	NULL
5	NULL
,	NULL
with	NULL
the	NULL
observed	NULL
frequencies	NULL
in	NULL
each	NULL
subgroup	NULL
(	NULL
Ayala	NULL
and	NULL
Kiger	NULL
,	NULL
1980	NULL
)	NULL
.	NULL

Results	NULL
Characterisation	NULL
of	NULL
Taq	NULL
)	NULL
polymorphism	NULL
Figures	NULL
2-4	NULL
show	NULL
representative	NULL
Southern	NULL
hybridisation	NULL
analyses	NULL
of	NULL
peripheral	NULL
leucocyte	NULL
genomic	NULL
DNA	NULL
using	NULL
Tagl	NULL
as	NULL
the	NULL
restriction	NULL
enzyme	NULL
and	NULL
the	NULL
region-specific	NULL
cDNA	NULL
fragments	NULL
hPR-1	NULL
,	NULL
hPR-2	NULL
and	NULL
hPR-3	NULL
respectively	NULL
as	NULL
the	NULL
probes	NULL
(	NULL
Figure	NULL
lb-d	NULL
)	NULL
.	NULL

A	NULL
single	NULL
,	NULL
two-allele	NULL
polymorphism	NULL
was	NULL
detected	NULL
,	NULL
comprising	NULL
Tl	NULL
,	NULL
represented	NULL
by	NULL
an	NULL
estimated	NULL
2.7	NULL
kb	NULL
fragment	NULL
,	NULL
and	NULL
T2	NULL
,	NULL
represented	NULL
by	NULL
an	NULL
estimated	NULL
1.9	NULL
kb	NULL
fragment	NULL
,	NULL
and	NULL
characterised	NULL
by	NULL
possession	NULL
of	NULL
an	NULL
additional	NULL
Tagl	NULL
restriction	NULL
site	NULL
with	NULL
respect	NULL
to	NULL
TI	NULL
.	NULL

Three	NULL
genotypes	NULL
were	NULL
detected	NULL
:	NULL
2.7	NULL
kb/2.7	NULL
kb	NULL
,	NULL
individuals	NULL
homozygous	NULL
for	NULL
the	NULL
Tl	NULL
allele	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
2.7	NULL
kb/l.9	NULL
kb	NULL
,	NULL
individuals	NULL
heterozygous	NULL
for	NULL
the	NULL
Tl	NULL
and	NULL
T2	NULL
alleles	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
;	NULL
and	NULL
1.9	NULL
kb/l.9	NULL
kb	NULL
individuals	NULL
homozygous	NULL
for	NULL
the	NULL
T2	NULL
allele	NULL
(	NULL
Figure	NULL
3	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Localisation	NULL
of	NULL
additional	NULL
Taq	NULL
!	NULL

restriction	NULL
site	NULL
hPR	NULL
cDNA	NULL
region	NULL
specific	NULL
probes	NULL
were	NULL
used	NULL
for	NULL
a	NULL
preliminary	NULL
localisation	NULL
of	NULL
the	NULL
additional	NULL
Tag	NULL
!	NULL

site	NULL
in	NULL
the	NULL
hPR	NULL
gene	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
three	NULL
Taql-digested	NULL
genomic	NULL
DNA	NULL
samples	NULL
probed	NULL
with	NULL
the	NULL
hPR-1	NULL
cDNA	NULL
probe	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
.	NULL

The	NULL
restriction	NULL
fragment	NULL
hybridisation	NULL
pattern	NULL
shows	NULL
four	NULL
invariant	NULL
bands	NULL
at	NULL
approximately	NULL
5.0	NULL
,	NULL
4.2	NULL
,	NULL
3.5	NULL
and	NULL
0.6	NULL
kb	NULL
and	NULL
the	NULL
two	NULL
variant	NULL
fragments	NULL
at	NULL
2.7	NULL
kb	NULL
and	NULL
1.9	NULL
kb	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
the	NULL
autoradiographic	NULL
pattern	NULL
when	NULL
the	NULL
hPR-2	NULL
cDNA	NULL
probe	NULL
(	NULL
Figure	NULL
1c	NULL
)	NULL
was	NULL
used	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
the	NULL
1.9	NULL
kb	NULL
fragment	NULL
(	NULL
representing	NULL
the	NULL
T2	NULL
allele	NULL
)	NULL
hybridised	NULL
with	NULL
the	NULL
hPR-2	NULL
cDNA	NULL
probe	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
extra	NULL
Tagl	NULL
site	NULL
3	NULL
'	NULL
to	NULL
nucleotide	NULL
position	NULL
2593	NULL
bp	NULL
(	NULL
numbered	NULL
from	NULL
ATG1	NULL
)	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
four	NULL
Tagql-digested	NULL
samples	NULL
probed	NULL
with	NULL
the	NULL
hPR-3	NULL
cDNA	NULL
probe	NULL
(	NULL
Figure	NULL
1d	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
neither	NULL
the	NULL
2.7	NULL
kb	NULL
nor	NULL
the	NULL
1.9	NULL
kb	NULL
fragment	NULL
was	NULL
detectable	NULL
by	NULL
this	NULL
probe	NULL
:	NULL
the	NULL
0.6	NULL
kb	NULL
fragment	NULL
was	NULL
detected	NULL
,	NULL
however	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
addi-	NULL
Figwre	NULL
2	NULL
Representative	NULL
Southern	NULL
analysis	NULL
of	NULL
Tagl-digested	NULL
genomic	NULL
DNA	NULL
hybridised	NULL
with	NULL
the	NULL
hPR-1	NULL
cDNA	NULL
probe	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
contain	NULL
samples	NULL
homozygous	NULL
for	NULL
the	NULL
2.7	NULL
kb	NULL
Tl	NULL
allele	NULL
.	NULL

Lane	NULL
3	NULL
contains	NULL
a	NULL
sample	NULL
heterozygous	NULL
for	NULL
the	NULL
Tl	NULL
and	NULL
T2	NULL
alleles	NULL
.	NULL

&	NULL
Figwre	NULL
3	NULL
Representative	NULL
autoradiographic	NULL
pattem	NULL
using	NULL
the	NULL
hPR-2	NULL
cDNA	NULL
fragment	NULL
to	NULL
probe	NULL
Tagql-digested	NULL
genomic	NULL
DNA	NULL
.	NULL

Three	NULL
genotypes	NULL
are	NULL
evident	NULL
:	NULL
2.7	NULL
kb/l.9	NULL
kb	NULL
,	NULL
individuals	NULL
heterozygous	NULL
for	NULL
the	NULL
Tl	NULL
and	NULL
T2	NULL
alleles	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
and	NULL
7	NULL
)	NULL
;	NULL
1.9	NULL
kb/1.9	NULL
kb	NULL
,	NULL
individuals	NULL
homozygous	NULL
for	NULL
T2	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
and	NULL
2.7	NULL
kb/	NULL
2.7	NULL
kb	NULL
,	NULL
individuals	NULL
homozygous	NULL
for	NULL
Tl	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Lane	NULL
3	NULL
was	NULL
empty	NULL
.	NULL

Progesterone	NULL
receptor	NULL
gene	NULL
RFLP	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
NJ	NULL
McKenna	NULL
et	NULL
al	NULL
aa	NULL
tional	NULL
Tagl	NULL
site	NULL
lies	NULL
5°	NULL
to	NULL
3133	NULL
bp	NULL
(	NULL
numbered	NULL
from	NULL
ATG	NULL
!	NULL

1	NULL
)	NULL
.	NULL

When	NULL
the	NULL
hPR-2	NULL
cDNA	NULL
probe	NULL
(	NULL
Figure	NULL
1c	NULL
)	NULL
was	NULL
used	NULL
,	NULL
the	NULL
1.9	NULL
kb	NULL
fragment	NULL
co-segregated	NULL
with	NULL
an	NULL
inconsistently	NULL
hybridising	NULL
smaller	NULL
fragment	NULL
of	NULL
0.8-1.0	NULL
kb	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
latter	NULL
fragment	NULL
is	NULL
composed	NULL
of	NULL
predominantly	NULL
intron	NULL
G	NULL
sequence	NULL
and	NULL
has	NULL
limited	NULL
sequence	NULL
overlap	NULL
with	NULL
the	NULL
hPR-2	NULL
cDNA	NULL
probe	NULL
compared	NULL
with	NULL
the	NULL
1.9	NULL
kb	NULL
fragment	NULL
.	NULL

These	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
location	NULL
of	NULL
an	NULL
additional	NULL
Tagl	NULL
site	NULL
in	NULL
intron	NULL
G	NULL
of	NULL
the	NULL
T2	NULL
hPR	NULL
allele	NULL
generating	NULL
,	NULL
upon	NULL
Tagl	NULL
diges-tion	NULL
,	NULL
a	NULL
1.9	NULL
kb	NULL
fragment	NULL
which	NULL
has	NULL
extensive	NULL
sequence	NULL
overlap	NULL
with	NULL
the	NULL
hPR-2	NULL
cDNA	NULL
probe	NULL
,	NULL
and	NULL
a	NULL
smaller	NULL
fragment	NULL
composed	NULL
of	NULL
predominantly	NULL
intron	NULL
G	NULL
sequence	NULL
.	NULL

It	NULL
is	NULL
notable	NULL
that	NULL
the	NULL
numbers	NULL
of	NULL
restriction	NULL
fragments	NULL
hybridising	NULL
to	NULL
each	NULL
of	NULL
the	NULL
three	NULL
cDNA	NULL
probes	NULL
hPR-1	NULL
,	NULL
hPR-2	NULL
and	NULL
hPR-3	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
location	NULL
of	NULL
the	NULL
Tagl	NULL
cDNA	NULL
restriction	NULL
sites	NULL
according	NULL
to	NULL
Kastner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
in	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
cDNA	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

Allelic	NULL
distribution	NULL
and	NULL
frequency	NULL
in	NULL
ovarian	NULL
cancer	NULL
patients	NULL
and	NULL
controls	NULL
Significant	NULL
differences	NULL
in	NULL
the	NULL
distribution	NULL
of	NULL
Tl	NULL
and	NULL
T2	NULL
alleles	NULL
were	NULL
observed	NULL
between	NULL
the	NULL
pooled	NULL
German/Irish	NULL
ovarian	NULL
carcinoma	NULL
cases	NULL
and	NULL
in	NULL
the	NULL
pooled	NULL
controls	NULL
(	NULL
P	NULL
<	NULL
0.025	NULL
)	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
difference	NULL
could	NULL
be	NULL
demonstrated	NULL
in	NULL
the	NULL
distribution	NULL
of	NULL
the	NULL
alleles	NULL
between	NULL
cases	NULL
and	NULL
controls	NULL
in	NULL
Ireland	NULL
(	NULL
P=	NULL
0.18	NULL
)	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
the	NULL
T2	NULL
allele	NULL
could	NULL
not	NULL
be	NULL
shown	NULL
to	NULL
differ	NULL
significantly	NULL
(	NULL
P	NULL
>	NULL
0.4	NULL
)	NULL
between	NULL
the	NULL
case	NULL
groups	NULL
of	NULL
both	NULL
countries	NULL
,	NULL
but	NULL
was	NULL
significantly	NULL
higher	NULL
in	NULL
the	NULL
Irish	NULL
control	NULL
group	NULL
than	NULL
in	NULL
the	NULL
German	NULL
control	NULL
group	NULL
Figure	NULL
4	NULL
Localisation	NULL
of	NULL
the	NULL
additional	NULL
Tag	NULL
!	NULL

site	NULL
in	NULL
the	NULL
hPR	NULL
gene	NULL
.	NULL

Lanes	NULL
1-4	NULL
contain	NULL
genomic	NULL
DNA	NULL
samples	NULL
heterozygous	NULL
for	NULL
the	NULL
Tl	NULL
and	NULL
T2	NULL
Tagl	NULL
hPR	NULL
alleles	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
hybridised	NULL
with	NULL
the	NULL
hPR-3	NULL
cDNA	NULL
probe	NULL
.	NULL

Differences	NULL
in	NULL
band	NULL
intensity	NULL
are	NULL
due	NULL
to	NULL
variations	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
DNA	NULL
loaded	NULL
.	NULL

Table	NULL
I	NULL
_	NULL
Distribution	NULL
and	NULL
frequencies	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
Tagl	NULL
alleles	NULL
in	NULL
pooled	NULL
,	NULL
Irish	NULL
and	NULL
German	NULL
ovarian	NULL
cancer	NULL
case	NULL
and	NULL
control	NULL
groups	NULL
Genotype	NULL
THT	NULL
!	NULL

THT2	NULL
T2/T2	NULL
T2	NULL
frequency	NULL
'	NULL
Group	NULL
Subgroup	NULL
n*	NULL
n	NULL
Frequency	NULL
(	NULL
95	NULL
%	NULL
CI	NULL
)	NULL
``	NULL
n	NULL
-	NULL
Frequency	NULL
(	NULL
95	NULL
%	NULL
CI	NULL
)	NULL
n	NULL
-	NULL
Frequency	NULL
(	NULL
95	NULL
%	NULL
Cl	NULL
)	NULL
(	NULL
95	NULL
%	NULL
CI	NULL
)	NULL
Pooled	NULL
_	NULL
Cases	NULL
67	NULL
43	NULL
64	NULL
(	NULL
52-75	NULL
)	NULL
23	NULL
35	NULL
(	NULL
24-47	NULL
)	NULL
1	NULL
1	NULL
(	NULL
0-4	NULL
)	NULL
0.19	NULL
(	NULL
0.12-0.25	NULL
)	NULL
Controls®	NULL
184	NULL
_	NULL
146	NULL
79	NULL
(	NULL
73-85	NULL
)	NULL
33	NULL
18	NULL
(	NULL
13-23	NULL
)	NULL
5	NULL
3	NULL
(	NULL
0-5	NULL
)	NULL
0.12	NULL
(	NULL
0.09-0.14	NULL
)	NULL
Irish	NULL
Cases	NULL
41	NULL
26	NULL
63.5	NULL
(	NULL
47-78	NULL
)	NULL
15	NULL
36.5	NULL
(	NULL
22-53	NULL
)	NULL
0	NULL
0	NULL
(	NULL
0-0	NULL
)	NULL
0.18	NULL
(	NULL
0.10-0.28	NULL
)	NULL
Controls®	NULL
83	NULL
58	NULL
70	NULL
(	NULL
60-80	NULL
)	NULL
21	NULL
25.5	NULL
(	NULL
16-34	NULL
)	NULL
4	NULL
5	NULL
(	NULL
1-9	NULL
)	NULL
0.17	NULL
(	NULL
0.12-0.23	NULL
)	NULL
German	NULL
-	NULL
Cases	NULL
26	NULL
17	NULL
65	NULL
(	NULL
46-85	NULL
)	NULL
8	NULL
31	NULL
(	NULL
12-50	NULL
)	NULL
1	NULL
4	NULL
(	NULL
0-11	NULL
)	NULL
0.19	NULL
(	NULL
0.08-0.30	NULL
)	NULL
Controls®	NULL
101	NULL
88	NULL
88	NULL
(	NULL
80-93	NULL
)	NULL
12	NULL
12	NULL
(	NULL
5-18	NULL
)	NULL
1	NULL
1	NULL
(	NULL
0-3	NULL
)	NULL
0.07	NULL
(	NULL
0.03-0.1	NULL
)	NULL
453	NULL
*Number	NULL
of	NULL
individuals	NULL
.	NULL

``	NULL
Numbers	NULL
in	NULL
parentheses	NULL
are	NULL
95	NULL
%	NULL
confidence	NULL
intervals	NULL
.	NULL

``	NULL
Allele	NULL
frequency	NULL
based	NULL
on	NULL
Hardy-Weinberg	NULL
equation	NULL
,	NULL
D	NULL
+	NULL
2pq	NULL
+	NULL
@	NULL
=	NULL
1	NULL
,	NULL
where	NULL
p	NULL
=	NULL
frequency	NULL
of	NULL
allele	NULL
T1	NULL
and	NULL
q=	NULL
frequency	NULL
of	NULL
allele	NULL
T2	NULL
in	NULL
a	NULL
given	NULL
subgroup	NULL
.	NULL

Hardy-Weinberg	NULL
distributions	NULL
were	NULL
calculated	NULL
from	NULL
values	NULL
of	NULL
p	NULL
and	NULL
q	NULL
obtained	NULL
.	NULL

y*	NULL
analysis	NULL
was	NULL
then	NULL
used	NULL
to	NULL
compare	NULL
these	NULL
expected	NULL
distributions	NULL
with	NULL
those	NULL
observed	NULL
.	NULL

All	NULL
subgroups	NULL
followed	NULL
the	NULL
expected	NULL
distribution	NULL
.	NULL

**Genotypic	NULL
distributions	NULL
of	NULL
subgroups	NULL
with	NULL
common	NULL
superscripts	NULL
differed	NULL
significantly	NULL
when	NULL
compared	NULL
by	NULL
y*	NULL
analysis	NULL
:	NULL
°P	NULL
<	NULL
0.025	NULL
,	NULL
*P	NULL
<	NULL
0.02	NULL
.	NULL

Progesterone	NULL
receptor	NULL
gone	NULL
RFLP	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
NJ	NULL
McKenna	NULL
et	NULL
af	NULL
454	NULL
(	NULL
P	NULL
<	NULL
0.02	NULL
)	NULL
.	NULL

The	NULL
distribution	NULL
of	NULL
the	NULL
two	NULL
alleles	NULL
in	NULL
each	NULL
group	NULL
exhibited	NULL
Mendelian	NULL
distribution	NULL
as	NULL
predicted	NULL
by	NULL
the	NULL
Hardy-Weinberg	NULL
equation	NULL
,	NULL
except	NULL
in	NULL
the	NULL
pooled	NULL
controls	NULL
,	NULL
in	NULL
which	NULL
significant	NULL
deviation	NULL
from	NULL
that	NULL
predicted	NULL
was	NULL
approached	NULL
(	NULL
P	NULL
<	NULL
0.15	NULL
)	NULL
.	NULL

Dé	NULL
A	NULL
Region-specific	NULL
analysis	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
demonstrated	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
ovarian	NULL
carcinoma-associated	NULL
germline	NULL
RFLP	NULL
in	NULL
intron	NULL
G	NULL
in	NULL
the	NULL
hormone-binding	NULL
domain-encoding	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
multiple	NULL
forms	NULL
of	NULL
the	NULL
progesterone	NULL
receptor	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
Scharl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Possible	NULL
explanations	NULL
include	NULL
multiple	NULL
polyadenylation	NULL
sites	NULL
,	NULL
differences	NULL
in	NULL
gene	NULL
regulatory	NULL
regions	NULL
or	NULL
alternative	NULL
intron	NULL
splicing	NULL
.	NULL

It	NULL
may	NULL
be	NULL
reasonably	NULL
speculated	NULL
that	NULL
the	NULL
polymorphism	NULL
we	NULL
have	NULL
localised	NULL
to	NULL
intron	NULL
G	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
has	NULL
consequences	NULL
for	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
regulatory	NULL
functions	NULL
of	NULL
the	NULL
hormone-binding	NULL
domain	NULL
,	NULL
possibly	NULL
through	NULL
premature	NULL
termination	NULL
of	NULL
the	NULL
progesterone	NULL
receptor	NULL
mRNA	NULL
transcript	NULL
or	NULL
other	NULL
faults	NULL
in	NULL
the	NULL
splicing	NULL
mechanism	NULL
.	NULL

Hormone	NULL
binding	NULL
and	NULL
regulated	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
progesterone	NULL
receptor	NULL
are	NULL
dependent	NULL
upon	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
complete	NULL
,	NULL
intact	NULL
hormone-binding	NULL
domain	NULL
:	NULL
deletion	NULL
of	NULL
part	NULL
of	NULL
this	NULL
region	NULL
induces	NULL
a	NULL
total	NULL
loss	NULL
of	NULL
hormone-binding	NULL
and	NULL
the	NULL
ability	NULL
to	NULL
activate	NULL
transcription	NULL
i	NULL
:	NULL
vitro	NULL
(	NULL
Dobson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
nature	NULL
of	NULL
the	NULL
polymorphism	NULL
we	NULL
have	NULL
1denuﬁedlsyettobedetermmed	NULL
,	NULL
anotheroonungencylsthat	NULL
it	NULL
is	NULL
a	NULL
neutral	NULL
polymorphism	NULL
co-segregating	NULL
with	NULL
other	NULL
progesterone	NULL
receptor	NULL
gene	NULL
aberrations	NULL
as	NULL
yet	NULL
undetected	NULL
,	NULL
as	NULL
has	NULL
been	NULL
suggested	NULL
in	NULL
the	NULL
case	NULL
of	NULL
an	NULL
intron	NULL
A	NULL
polymorphism	NULL
in	NULL
the	NULL
oestrogen	NULL
receptor	NULL
gene	NULL
in	NULL
breast	NULL
cancer	NULL
(	NULL
Yaich	NULL
et	NULL
el	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
demonstration	NULL
of	NULL
the	NULL
tumour-suppressive	NULL
properties	NULL
of	NULL
chromosome	NULL
11	NULL
in	NULL
an	NULL
ovarian	NULL
cancer	NULL
cell	NULL
line	NULL
(	NULL
Cao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
as	NULL
well	NULL
as	NULL
loss	NULL
of	NULL
heterozygosity	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
(	NULL
Foulkes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
at	NULL
the	NULL
hPR	NULL
gene	NULL
locus	NULL
11q22-q23	NULL
(	NULL
Rousseau-Merck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Mattei	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
raise	NULL
the	NULL
References	NULL
AYALA	NULL
FJ	NULL
AND	NULL
KIGER	NULL
A	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

Modern	NULL
Genetics	NULL
.	NULL

Benjamin	NULL
ings	NULL
:	NULL
Menlo	NULL
Park	NULL
,	NULL
CA	NULL
.	NULL

CAO	NULL
Q	NULL
,	NULL
CEDRONE	NULL
E	NULL
,	NULL
BARRETT	NULL
C	NULL
AND	NULL
WANG	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Suppression	NULL
of	NULL
in	NULL
vitro	NULL
growth	NULL
of	NULL
ovarian	NULL
carcinoma	NULL
cells	NULL
by	NULL
microcell-mediated	NULL
chromosome	NULL
11	NULL
transfer	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Hum	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
53	NULL
,	NULL
1517	NULL
.	NULL

CHADHA	NULL
S	NULL
,	NULL
RAO	NULL
BR	NULL
,	NULL
SLOTMAN	NULL
BJ	NULL
,	NULL
van	NULL
VROONHOVEN	NULL
CCJ	NULL
AND	NULL
VAN	NULL
DER	NULL
KWAST	NULL
TH	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

An	NULL
immunohistochemical	NULL
evaluation	NULL
of	NULL
androgen	NULL
and	NULL
receptors	NULL
in	NULL
ovarian	NULL
tumours	NULL
.	NULL

Hum	NULL
.	NULL

Pathol	NULL
.	NULL

,	NULL
24	NULL
,	NULL
90-95	NULL
.	NULL

CLIFFORD-BROUGHAM	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Human	NULL
progesterone	NULL
receptor	NULL
cDNA	NULL
;	NULL
molecular	NULL
cloning	NULL
and	NULL
use	NULL
in	NULL
RFLP	NULL
analysis	NULL
of	NULL
human	NULL
DNA	NULL
,	NULL
PhD	NULL
Thesis	NULL
.	NULL

National	NULL
University	NULL
of	NULL
Ireland	NULL
.	NULL

DOBSON	NULL
ADW	NULL
,	NULL
CONNEELY	NULL
OM	NULL
,	NULL
BEATTIE	NULL
W	NULL
,	NULL
MAXWELL	NULL
BL	NULL
,	NULL
MAK	NULL
P	NULL
,	NULL
TSAI	NULL
M-J	NULL
,	NULL
SCHRADER	NULL
WT	NULL
AND	NULL
O'MALLEY	NULL
BW	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Muta-tional	NULL
analysis	NULL
of	NULL
the	NULL
chicken	NULL
progesterone	NULL
receptor	NULL
.	NULL

J.	NULL
Bio/	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
264	NULL
,	NULL
4207-4211	NULL
.	NULL

FOULKES	NULL
WD	NULL
,	NULL
CAMPBELL	NULL
IG	NULL
,	NULL
STAMP	NULL
GW	NULL
AND	NULL
TROWSDALE	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Loss	NULL
of	NULL
heterozygosity	NULL
and	NULL
amplification	NULL
on	NULL
chromosome	NULL
11q	NULL
in	NULL
human	NULL
ovarian	NULL
cancer	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
67	NULL
,	NULL
268-273	NULL
.	NULL

FUQUA	NULL
SAW	NULL
,	NULL
HILL	NULL
SM	NULL
,	NULL
CHAMNESS	NULL
GC	NULL
,	NULL
BENEDIX	NULL
MG	NULL
,	NULL
GREENE	NULL
GL	NULL
,	NULL
O'MALLEY	NULL
BW	NULL
AND	NULL
MCGUIRE	NULL
WL	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Progesterone	NULL
receptor	NULL
gene	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
in	NULL
human	NULL
breast	NULL
tumors	NULL
.	NULL

J.	NULL
Nat	NULL
!	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
83	NULL
,	NULL
1157-1160	NULL
.	NULL

HAMPTON	NULL
GM	NULL
,	NULL
PENNY	NULL
LA	NULL
,	NULL
BAERGEN	NULL
RN	NULL
,	NULL
LARSON	NULL
A	NULL
,	NULL
BREWER	NULL
C	NULL
,	NULL
LIAO	NULL
S	NULL
,	NULL
BUSBY-EARLE	NULL
RM	NULL
,	NULL
WILLIAMS	NULL
AWR	NULL
,	NULL
STEEL	NULL
CM	NULL
,	NULL
BIRD	NULL
CC	NULL
,	NULL
STANBRIDGE	NULL
EJ	NULL
AND	NULL
EVANS	NULL
GA.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Loss	NULL
of	NULL
heterozygosity	NULL
in	NULL
cervical	NULL
carcinoma	NULL
:	NULL
subchromosomal	NULL
localization	NULL
of	NULL
a	NULL
putative	NULL
tumour	NULL
r	NULL
gene	NULL
to	NULL
chromosome	NULL
11q22-24	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
6953-6957	NULL
.	NULL

HOLLSTEIN	NULL
M	NULL
,	NULL
SIDRANSKY	NULL
D	NULL
,	NULL
VOGELSTEIN	NULL
B	NULL
AND	NULL
HARRIS	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

p53	NULL
mutations	NULL
in	NULL
human	NULL
cancers	NULL
.	NULL

Science	NULL
,	NULL
253	NULL
,	NULL
49-53	NULL
.	NULL

KASTNER	NULL
P	NULL
,	NULL
KRUST	NULL
A	NULL
,	NULL
TURCOTTE	NULL
B	NULL
,	NULL
STROPP	NULL
U	NULL
,	NULL
TORA	NULL
L	NULL
,	NULL
GRONEMEYER	NULL
H	NULL
AND	NULL
CHAMBON	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Two	NULL
distinct	NULL
estsrogen-regulated	NULL
promoters	NULL
generate	NULL
transcripts	NULL
encoding	NULL
the	NULL
two	NULL
functionally	NULL
different	NULL
human	NULL
progesterone	NULL
receptor	NULL
forms	NULL
A	NULL
and	NULL
B.	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
1603-1614.	NULL
question	NULL
of	NULL
a	NULL
possible	NULL
tumour-suppressive	NULL
role	NULL
for	NULL
the	NULL
hPR	NULL
.	NULL

The	NULL
11q22-q24	NULL
locus	NULL
contains	NULL
a	NULL
tumour-suppressor	NULL
gene	NULL
relevant	NULL
to	NULL
breast	NULL
cancer	NULL
(	NULL
Stickland	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
and	NULL
cervical	NULL
carcinoma	NULL
(	NULL
Hampton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
give	NULL
credence	NULL
to	NULL
the	NULL
possibility	NULL
of	NULL
a	NULL
tumour-suppressive	NULL
role	NULL
for	NULL
the	NULL
hPR	NULL
gene	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

Considering	NULL
the	NULL
hypothesis	NULL
of	NULL
Knudson	NULL
(	NULL
1971	NULL
)	NULL
that	NULL
one	NULL
defective	NULL
copy	NULL
of	NULL
a	NULL
tumour-suppressive	NULL
gene	NULL
is	NULL
inherited	NULL
and	NULL
the	NULL
other	NULL
subject	NULL
to	NULL
a	NULL
somatic	NULL
mutation	NULL
,	NULL
the	NULL
over-representation	NULL
of	NULL
the	NULL
TI/T2	NULL
heterozygote	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
patients	NULL
suggests	NULL
a	NULL
possible	NULL
scenario	NULL
:	NULL
that	NULL
these	NULL
individuals	NULL
have	NULL
inherited	NULL
a	NULL
defective	NULL
copy	NULL
of	NULL
the	NULL
hPR	NULL
gene	NULL
and	NULL
that	NULL
the	NULL
other	NULL
is	NULL
subject	NULL
to	NULL
a	NULL
somatic	NULL
mutation	NULL
.	NULL

Long-term	NULL
prospective	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
monitor	NULL
the	NULL
incidence	NULL
of	NULL
ovarian	NULL
carcinoma	NULL
in	NULL
the	NULL
control	NULL
group	NULL
,	NULL
especially	NULL
in	NULL
those	NULL
individuals	NULL
with	NULL
the	NULL
T2/T2	NULL
genotype	NULL
.	NULL

Whereas	NULL
the	NULL
frequency	NULL
of	NULL
the	NULL
T2	NULL
allele	NULL
is	NULL
similar	NULL
in	NULL
the	NULL
Irish	NULL
and	NULL
German	NULL
case	NULL
groups	NULL
,	NULL
the	NULL
higher	NULL
frequency	NULL
of	NULL
T2	NULL
in	NULL
the	NULL
Irish	NULL
controls	NULL
led	NULL
to	NULL
a	NULL
smaller	NULL
difference	NULL
in	NULL
T2	NULL
frequency	NULL
between	NULL
the	NULL
Irish	NULL
case	NULL
and	NULL
control	NULL
groups	NULL
,	NULL
hence	NULL
significance	NULL
could	NULL
not	NULL
be	NULL
established	NULL
in	NULL
this	NULL
population	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
distribution	NULL
of	NULL
the	NULL
Tagl	NULL
RFLP	NULL
alleles	NULL
approaches	NULL
significant	NULL
deviation	NULL
from	NULL
that	NULL
predicted	NULL
by	NULL
the	NULL
Hardy-Weinberg	NULL
equation	NULL
(	NULL
P	NULL
<	NULL
0.15	NULL
)	NULL
in	NULL
the	NULL
pooled	NULL
controls	NULL
will	NULL
require	NULL
further	NULL
investigation	NULL
.	NULL

To	NULL
conclude	NULL
,	NULL
the	NULL
current	NULL
data	NULL
show	NULL
an	NULL
association	NULL
between	NULL
a	NULL
Taql	NULL
RFLP	NULL
and	NULL
incidence	NULL
of	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

This	NULL
polymorphism	NULL
is	NULL
associated	NULL
with	NULL
ovarian	NULL
cancer	NULL
at	NULL
a	NULL
germline	NULL
level	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
tumour	NULL
level	NULL
.	NULL

Further	NULL
work	NULL
will	NULL
characterise	NULL
its	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

Acknowledgements	NULL
The	NULL
authors	NULL
wish	NULL
to	NULL
thank	NULL
Gerry	NULL
Killeen	NULL
for	NULL
reading	NULL
the	NULL
manuscript	NULL
and	NULL
Don	NULL
Collins	NULL
for	NULL
photography	NULL
.	NULL

Financial	NULL
support	NULL
for	NULL
this	NULL
work	NULL
was	NULL
provided	NULL
by	NULL
a	NULL
United	NULL
Kingdom-Ireland	NULL
Postgraduate	NULL
Exchange	NULL
Scholarship	NULL
held	NULL
by	NULL
NJMcK	NULL
,	NULL
an	NULL
Institutional	NULL
Grant	NULL
from	NULL
the	NULL
University	NULL
of	NULL
Ulm	NULL
held	NULL
by	NULL
DGK	NULL
,	NULL
and	NULL
by	NULL
American	NULL
Biogenetic	NULL
Sciences	NULL
,	NULL
USA	NULL
.	NULL

Funding	NULL
was	NULL
also	NULL
provided	NULL
in	NULL
part	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Health	NULL
Research	NULL
Board	NULL
,	NULL
Ireland	NULL
and	NULL
the	NULL
Irish	NULL
Cancer	NULL
Society	NULL
to	NULL
DRH	NULL
.	NULL

KIEBACK	NULL
DG	NULL
,	NULL
RUNNEBAUM	NULL
IB	NULL
,	NULL
MOEBUS	NULL
VJ	NULL
,	NULL
KREIENBERG	NULL
R	NULL
,	NULL
MCCAMANT	NULL
SK	NULL
,	NULL
EDWARDS	NULL
CL	NULL
,	NULL
JONES	NULL
LA	NULL
,	NULL
TSAI	NULL
M-J	NULL
AND	NULL
O'MALLEY	NULL
BW	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Chicken	NULL
ovalbumin	NULL
upstream	NULL
promoter	NULL
transcription	NULL
factor	NULL
(	NULL
COUP-TF	NULL
)	NULL
:	NULL
an	NULL
orphan	NULL
steroid	NULL
receptor	NULL
with	NULL
a	NULL
specific	NULL
pattern	NULL
of	NULL
differential	NULL
ion	NULL
in	NULL
human	NULL
ovarian	NULL
cancer	NULL
cell	NULL
lines	NULL
.	NULL

Gynecol	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
51	NULL
,	NULL
167-170	NULL
.	NULL

KNUDSON	NULL
AG	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
.	NULL

Mutation	NULL
and	NULL
cancer	NULL
:	NULL
statistical	NULL
study	NULL
of	NULL
retinoblastoma	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
68	NULL
,	NULL
820-823	NULL
.	NULL

MATTEI	NULL
MG	NULL
,	NULL
KRUST	NULL
A	NULL
,	NULL
STROPP	NULL
U	NULL
,	NULL
MATTEI	NULL
J-F	NULL
AND	NULL
CHAMBON	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

Assignment	NULL
of	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
gene	NULL
to	NULL
the	NULL
q22	NULL
band	NULL
of	NULL
chromosome	NULL
11	NULL
.	NULL

Hum	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
78	NULL
,	NULL
96-97	NULL
.	NULL

MILLER	NULL
SA	NULL
,	NULL
DYKES	NULL
DD	NULL
AND	NULL
POLESKY	NULL
HF	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

A	NULL
simple	NULL
salting-out	NULL
procedure	NULL
for	NULL
extracting	NULL
DNA	NULL
from	NULL
human	NULL
nucleated	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
16	NULL
,	NULL
315	NULL
.	NULL

MISRAHI	NULL
M	NULL
,	NULL
ATGER	NULL
M	NULL
,	NULL
D'AURIOL	NULL
L	NULL
,	NULL
LOOSFELT	NULL
H	NULL
,	NULL
MERIEL	NULL
C	NULL
,	NULL
FRIDLANSKY	NULL
F	NULL
,	NULL
GUIOCHON-MANTEL	NULL
A	NULL
,	NULL
GALIBERT	NULL
F	NULL
AND	NULL
MILGROM	NULL
E.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Complete	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
cDNA	NULL
deduced	NULL
from	NULL
cloned	NULL
cDNA	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
143	NULL
,	NULL
740-748	NULL
.	NULL

MISRAHI	NULL
M	NULL
,	NULL
VENENCIE	NULL
P-Y	NULL
,	NULL
SAUGIER-VEBER	NULL
P	NULL
,	NULL
SAR	NULL
S	NULL
,	NULL
DESSEN	NULL
P	NULL
AND	NULL
MILGROM	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
gene	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1216	NULL
,	NULL
289-292	NULL
.	NULL

NOGUCHI	NULL
T	NULL
,	NULL
KITAWAKI	NULL
J	NULL
,	NULL
TAMURA	NULL
T	NULL
,	NULL
KIM	NULL
T	NULL
,	NULL
KANNO	NULL
H	NULL
,	NULL
YAMAMOTO	NULL
T	NULL
AND	NULL
OKADA	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Relationship	NULL
between	NULL
aromatase	NULL
activity	NULL
and	NULL
steroid	NULL
receptor	NULL
levels	NULL
in	NULL
ovarian	NULL
tumours	NULL
from	NULL
post-menopausal	NULL
women	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
44	NULL
,	NULL
657-660	NULL
.	NULL

ROUSSEAU-MERCK	NULL
MF	NULL
,	NULL
MISRAHI	NULL
M	NULL
,	NULL
LOOSFELT	NULL
H	NULL
,	NULL
MILGROM	NULL
E	NULL
AND	NULL
BERGER	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
human	NULL
progesterone	NULL
receptor	NULL
gene	NULL
to	NULL
chromosome	NULL
11q22-q23	NULL
.	NULL

Hum	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
77	NULL
,	NULL
280-282	NULL
.	NULL

SANDY	NULL
MS	NULL
,	NULL
CHIOCCA	NULL
SM	NULL
AND	NULL
CERUTTI	NULL
PA.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Genotypic	NULL
analysis	NULL
of	NULL
mutations	NULL
in	NULL
Tagl	NULL
restriction	NULL
recognition	NULL
sites	NULL
by	NULL
restniction	NULL
fragment	NULL
length	NULL
polymorphism/polymerase	NULL
chain	NULL
reac-tion	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
890-894	NULL
SCHARL	NULL
A	NULL
,	NULL
LORINCZ	NULL
MA	NULL
,	NULL
GREENE	NULL
GL	NULL
AND	NULL
HOLT	NULL
JA	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Ovarian	NULL
carcinomas	NULL
express	NULL
several	NULL
forms	NULL
of	NULL
the	NULL
progesterone	NULL
receptor	NULL
.	NULL

Arch	NULL
.	NULL

Gynecol	NULL
.	NULL

Obstet	NULL
.	NULL

,	NULL
250	NULL
,	NULL
181-182	NULL
.	NULL

SCULLY	NULL
SR.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Pathology	NULL
of	NULL
ovarian	NULL
carcinoma	NULL
.	NULL

In	NULL
Ovarian	NULL
Malignancies	NULL
,	NULL
Piver	NULL
SM	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

pp	NULL
.	NULL

72-95	NULL
.	NULL

Churchill	NULL
Livingstone	NULL
:	NULL
Edinburgh	NULL
.	NULL

SLOTMAN	NULL
BJ	NULL
.	NULL

NAUTA	NULL
JJ	NULL
AND	NULL
RAMANATH-RAO	NULL
BR	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Survival	NULL
of	NULL
patients	NULL
with	NULL
ovarian	NULL
cancer	NULL
:	NULL
apart	NULL
from	NULL
stage	NULL
and	NULL
grade	NULL
,	NULL
tumour	NULL
progesterone	NULL
receptor	NULL
content	NULL
is	NULL
a	NULL
prognostic	NULL
indicator	NULL
.	NULL

Cancer	NULL
,	NULL
66	NULL
,	NULL
740-744	NULL
.	NULL

STICKLAND	NULL
JE	NULL
,	NULL
TOMLINSON	NULL
IP	NULL
,	NULL
LEE	NULL
AS	NULL
,	NULL
EVANS	NULL
MF	NULL
AND	NULL
MCGEE	NULL
JO	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Allelic	NULL
loss	NULL
on	NULL
chromosome	NULL
11q	NULL
is	NULL
a	NULL
frequent	NULL
event	NULL
in	NULL
breast	NULL
cancer	NULL
(	NULL
abstract	NULL
)	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
66	NULL
(	NULL
Suppl	NULL
.	NULL

XVID	NULL
)	NULL
,	NULL
3	NULL
.	NULL

Progesterone	NULL
receptor	NULL
gene	NULL
RFLP	NULL
in	NULL
ovarian	NULL
carcinoma	NULL
NJ	NULL
McKenna	NULL
et	NULL
al	NULL
WANLESS	NULL
C	NULL
,	NULL
BARKER	NULL
S	NULL
,	NULL
PUDDEFOOT	NULL
JR	NULL
,	NULL
PANAHY	NULL
C.	NULL
GOODE	NULL
AW	NULL
.	NULL

VINSON	NULL
GP	NULL
AND	NULL
PHILLIPS	NULL
IR	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Somatic	NULL
change	NULL
in	NULL
the	NULL
estrogen	NULL
receptor	NULL
gene	NULL
associated	NULL
with	NULL
altered	NULL
expression	NULL
of	NULL
the	NULL
progesterone	NULL
receptor	NULL
.	NULL

Anticancer	NULL
Res	NULL
.	NULL

,	NULL
11	NULL
,	NULL
139-142	NULL
.	NULL

YAICH	NULL
L	NULL
,	NULL
DUPONT	NULL
WD	NULL
,	NULL
CAVENER	NULL
DR	NULL
AND	NULL
PARL	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
Pvull	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
and	NULL
exon	NULL
structure	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
gene	NULL
in	NULL
breast	NULL
cancer	NULL
and	NULL
peripheral	NULL
blood	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
52	NULL
,	NULL
77-83	NULL
.	NULL

PA	NULL
455	NULL

